About Technology Transfer Agents

By Author: Ibrahim Machiwala
Total Articles: 463
Comment this article

There are no direct financial fruits from merely owning a patent. There are a lot of patents and products which are lying useless in federally funded universities and research laboratories across the country. A patent or product must be adopted, purchased or leased by a corporation for development.

The Technology Transfer Agents are present to complete the cycle of innovation by bringing to the market, products and services resulting from federally funded research institutions. They are also considered the catalysts for innovation.

The only reason for being a transfer agent is to make federally funded research available to private industry, for discovering new applications for new inventions, technologies, and products. To return royalties and revenue back to the research agency.

More than 700 laboratories and research centers apply their research and development skills and expertise for the advancement of science and represent almost all federal departments and agencies- conducting over $100 billion in research and development annually and employ more than 100,000 scientists.

Their science ...
... makes our lives safer, more convenient, and more fulfilling from medicine to transportation to communications, these research facilities investigate everything that is known and extract knowledge from the previously unknown. These scientists' efforts, desires, and creativity are unparalleled.

But all of this work is for nothing if the talents of the genius are not unleashed. It is really necessary that the mind-blowing developments happening behind laboratory doors be transferred from the logical existence to practical existence.

To take full advantage on the nation's investment in federal research, the expertise and technology should be brought to the marketplace, which not only enhances the nation's socioeconomic well-being in the global marketplace, but security and prominence is also secured.

This transfer is accomplished through the outstanding work of scientists, agency representatives, and technology transfer professionals. This achievement requires a vision, a plan, and a methodology.

In 2003, LipidLabs acquired and commercialized the Advanced Lipoprotein Fingerprinting Screening technology that allows doctors to better identify health risks. After maturing the technology, it was sold it to Spectracell Laboratories, Inc. for $354,000 and retained a royalty interest, which is then distributed to the prior shareholders as a dividend.

Built on the strength of success, Lipid continues to capitalize, keep alive and deliver the next generation of technology from R&D Facilities like Texas A&M to the marketplace.

LipidLabs, Inc, partners with Fortune 500 companies, small enterprises, universities, and research institutions bringing innovations to market. Finding or funding private and publicly held corporations LipidLabs turns research into reality.

LipidLabs has the vision, plan, and methodology with the tools and services to ensure that the efforts of federal engineers and scientists are not left on a shelf. LipidLabs develops and tests transfer methods, addresses barriers to the process, helps the marketing process, and provides additional funds for necessary product development. LipidLabs offers capitalization, private funding, and fast track commercialization.

Three distinct R&D Commercialization Segments form the foundation of LipidLabs Technology Transfer Services: 1) Nano-Technology and Applied Materials; 2) Bimolecular Sciences, Medical Health and Wellness; and 3) Manufacturing, Transportation and Storage.

In most cases, LipidLabs will obtain an exclusive license and marketing rights from the university or research facility that will provide for royalty payments to the university from profits generated by that technology. In some cases, LipidLabs actually purchases the patents to products under development.

LipidLabs Growth Strategy is the first strategy to simply increase number and value of technology transfers valuations. Second strategy is to expand customer and university supplier base.

LipidLabs expects to continue to develop new technologies and to leverage on the millions of dollars of research grants that universities spend developing these products.